Strong progress in vaccine development with transition to clinical phase, robust financing from grants and share issues, and a widened pipeline. Net loss increased due to higher R&D costs, but cash position and equity improved significantly.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.